Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Turn Therapeutics Inc. - Common Stock (NQ:TTRX)

12.69 -0.69 (-5.16%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	135,665
Open	13.30
Bid (Size)	11.90 (3,300)
Ask (Size)	14.25 (200)
Prev. Close	13.38
Today's Range	12.63 - 14.25
52wk Range	2.570 - 26.50
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

September 10, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer

September 09, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Performance

YTD	+170.6%	+170.6%
1 Month	+28.7%	+28.7%
3 Month	+97.7%	+97.7%
6 Month	+247.7%	+247.7%
1 Year	+81.3%	+81.3%

More News

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

August 20, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

August 12, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

July 28, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout ↗

July 11, 2026

Via MarketBeat

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

July 07, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

July 06, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

June 01, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

May 27, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

May 19, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

May 18, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 11, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

March 31, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group

March 24, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs

February 17, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences

February 09, 2026

From Turn Therapeutics Inc.

Via Business Wire

Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

January 07, 2026

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 13, 2025

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.

November 11, 2025

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine

November 11, 2025

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications

November 04, 2025

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline

October 30, 2025

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones

October 22, 2025

From Turn Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Turn Therapeutics Inc. - Common Stock publicly traded?

Yes, Turn Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Turn Therapeutics Inc. - Common Stock trade on?

Turn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Turn Therapeutics Inc. - Common Stock?

The ticker symbol for Turn Therapeutics Inc. - Common Stock is TTRX on the Nasdaq Stock Market

What is the current price of Turn Therapeutics Inc. - Common Stock?

The current price of Turn Therapeutics Inc. - Common Stock is 12.69

When was Turn Therapeutics Inc. - Common Stock last traded?

The last trade of Turn Therapeutics Inc. - Common Stock was at 09/11/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.